Success Metrics

Clinical Success Rate

94.6%

Based on 35 completed trials

Completion Rate

95%(35/37)

Active Trials

6(13%)

Results Posted

46%(16 trials)

Terminated

2(4%)

Phase Distribution

Ph early_phase_1

Ph phase_2

23%

Ph phase_3

15%

Ph phase_1

Ph phase_4

17%

Ph not_applicable

27%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution46 total trials

Early Phase 1First-in-human

4(8.7%)

Phase 1Safety & dosage

3(6.5%)

Phase 2Efficacy & side effects

11(23.9%)

Phase 3Large-scale testing

7(15.2%)

Phase 4Post-market surveillance

8(17.4%)

N/ANon-phased studies

13(28.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.1%

35 of 38 finished

Non-Completion Rate

7.9%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Completed(35)

Terminated(3)

Other(2)

Detailed Status

Completed35

Recruiting6

Terminated2

unknown2

Enrolling by invitation1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

94.6%

Most Advanced

Phase 4

Trials by Phase

Early Phase 14 (8.7%)

Phase 13 (6.5%)

Phase 211 (23.9%)

Phase 37 (15.2%)

Phase 48 (17.4%)

N/A13 (28.3%)

Trials by Status

completed3573%

enrolling_by_invitation12%

terminated24%

unknown24%

withdrawn12%

not_yet_recruiting12%

recruiting613%

Recent Activity

6 active trials

Showing 5 of 48

recruitingphase_2

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

NCT06200155

recruitingearly_phase_1

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

NCT06858332

View all 48 trials

Clinical Trials (48)

Showing 20 of 48 trialsScroll for more

NCT06200155Phase 2

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Recruiting

NCT06175403Early Phase 1

A Study of Niacin Regulation

Recruiting

NCT01275300Not Applicable

Biosynthesis of PGD2 in Vivo

Completed

NCT04234217Not Applicable

Mechanisms of Prediabetic States in Sleep Apnea

Recruiting

NCT06858332

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Recruiting

NCT05452772Phase 2

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Recruiting

NCT04424225Phase 1

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

Terminated

NCT04464070Early Phase 1

Pathways of Eicosanoid Metabolism

Enrolling By Invitation

NCT00302744Phase 1

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Completed

NCT03808961Not Applicable

Low Dose Niacin (Vitamin B3) for Parkinson's Disease

Terminated

NCT03867500Early Phase 1

Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus

Completed

NCT06444243Phase 2

Psilocybin-assisted Therapy for Alcohol Use Disorder

Not Yet Recruiting

NCT03752918Phase 1

The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

Withdrawn

NCT04630964Phase 2

The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density

Completed

NCT05709353Phase 2

MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder

Recruiting

NCT03866174Phase 2

A Study of Psilocybin for Major Depressive Disorder (MDD)

Completed

NCT03973203Not Applicable

Niacin Supplementation in Healthy Controls and Mitochondrial Myopathy Patients

Completed

NCT00715273Phase 4

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

Completed

NCT04703361Phase 2

Effects of Ketones and Niacin in Heart Failure Patients

Completed

NCT03462680Not Applicable

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

Completed

Drug Details

Intervention Type: OTHER
Total Trials: 48